Companies STORM Therapeutics

First-in-class therapies targeting RNA modifying enzymes


STORM Therapeutics pioneering founders have led the discovery of the role that RNA modifying enzymes play in a variety of diseases, including cancer and viral infection.

Leveraging these biological insights, the team at STORM Therapeutics have progressed the first drug capable of targeting these enzymes therapeutically into the clinic, potentially opening an entirely new class of therapeutics.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More